Back to results

Randomized Trial of a Nutritional Supplement in Alzheimer's Disease

Primary Purpose

Alzheimer's Disease

Status

Completed

Phase

Phase 3

Locations

United States

Study Type

Interventional

Intervention

Resveratrol with Glucose, and Malate

Placebo

About this trial

This is an interventional treatment trial for Alzheimer's Disease focused on measuring Alzheimer's Disease, Dementia, Nutritional Supplement, Resveratrol

Eligibility Criteria

50 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Consenting individuals as defined by IRB guidelines
NINCDS/ADRDA criteria for probable AD
Community dwelling
Age: greater than or equal to 50 years
MMSE between 12 and 26, inclusive
Stable medical condition for 3 months prior to screening visit
Stable doses of (non excluded) medications with central nervous system activity for 4 weeks prior to the screening visit (For cholinesterase inhibitors there should be no plan of dose escalation)
Physically acceptable for this study as confirmed by medical history, physical exam, neurologic exam and clinical laboratory tests
Supervision available for administration of study medications
Study partner to accompany subject to all scheduled visits and complete informant-based assessments.
Fluent in English or Spanish
Modified Hachinski < 4
CT or MRI since onset of memory impairment demonstrating absence of clinically significant focal lesion (One lacune in a non-critical brain region is acceptable)
Able to complete baseline assessments
6 years of education, or work history sufficient to exclude mental retardation
Able to ingest oral medication

Exclusion Criteria:

Active liver disease or persistent elevation in serum transaminase
Severe renal disease
- Hx of diabetes mellitus (both insulin-dependent and non-insulin-dependent) or blood glucose >150 mg/dl
Active neoplastic disease (skin tumors other than melanoma are not exclusionary; subjects with stable prostate cancer or other stable cancers may be included at the discretion of the PI (Sano))
Use of another investigational agent within 2 months of the screening visit
History of clinically significant stroke
Current evidence or history in the past 2 years of seizures, head injury with loss of consciousness and/or immediate confusion after the injury
Current DSM-IV criteria-based diagnosis for major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse.
Blindness, deafness, language difficulties or any other disability which may interfere with testing ability
In female subjects, no history of menopause
Use of medications containing aluminum hydroxide, including anti-ulcer antacids such as Alternagel, Amphojel, Alu-tab, Maalox and Mylanta

Sites / Locations

James J. Peters VA Medical Center, Bronx, NY

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Arm 1

Arm 2

Arm Description

Liquid placebo

Liquid Resveratrol with Glucose, and Malate

Outcomes

Primary Outcome Measures

Alzheimer Disease Assessment Scale (ADAScog)

Secondary Outcome Measures

CGIC

Full Information

NCT ID

NCT00678431

First Posted

January 7, 2008

Last Updated

November 13, 2012

Sponsor

US Department of Veterans Affairs

Collaborators

Alzheimer's Association, Icahn School of Medicine at Mount Sinai

1. Study Identification

Unique Protocol Identification Number

NCT00678431

Brief Title

Randomized Trial of a Nutritional Supplement in Alzheimer's Disease

Official Title

A Single Center, Multi-site, Randomized, Double-blind, Placebo-controlled Trial of Resveratrol With Glucose and Malate (RGM) to Slow the Progression of Alzheimer's Disease

Study Type

Interventional

2. Study Status

Record Verification Date

November 2012

Overall Recruitment Status

Completed

Study Start Date

January 2008 (undefined)

Primary Completion Date

December 2010 (Actual)

Study Completion Date

June 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

US Department of Veterans Affairs

Collaborators

Alzheimer's Association, Icahn School of Medicine at Mount Sinai

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

Alzheimer's disease (AD), one of the leading causes of morbidity and mortality in the elderly is characterized by progressive cognitive decline and certain neuropathological features. Currently, there is great interest in the well-documented mitochondrial (oxidative) lesion in AD. Disturbed oxidative metabolism is a well described abnormality in AD. Several observational studies have shown that moderate consumption of wine is associated with a lower incidence of Alzheimer's disease (Truelsen et al., 2002; Luchsinger et al., 2004). Wine is enriched in antioxidant compounds with potential neuroprotective activities. In the early 1990s the presence of Resveratrol in red wine was detected where it is suspected to afford antioxidant and neuroprotective properties (Miller and Rice-Evans, 1995). Blass and Gordon (2004) have demonstrated positive effects in AD with an oral preparation of glucose, malate and resveratrol. Glucose is the physiological precursor of the substrates of oxidative metabolism in the brain, malate is a primer of the energy-providing Krebs-cycle. Glucose and malate therefore can provide reducing equivalents (electrons) to regenerate the reduced form of resveratrol, and do so under the normal regulation of brain cell metabolism. All three ingredients are classified by the FDA as Generally Recognized As Safe.

Detailed Description

Subjects will be assessed by their capacity to consent by a psychiatrist independent of this study. Subjects who are determined to have capacity will sign consent. For subjects determined to lack capacity consent will be obtained from their surrogate. Subjects lacking in capacity must nonetheless provide verbal assent to participation in this study. After informed consent is obtained, subjects will be screened for eligibility to participate in the study. Screening comprises of medical history, physical exam, neurological exam, and a MMSE. All of the above are performed for research purposes. Further evaluation of medical problems that are identified in the course of screening will be obtained as part of standard clinical care. For example, if an abnormality requiring further evaluation is detected on blood tests the subsequent evaluation will be conducted as standard clinical care. Subjects who meet eligibility criteria will be baseline within 4 weeks. Eligible subjects will not be asked to stop any medication they may currently be on before the study begins. Eligible subjects will be randomized to receive either a mixture of glucose, malate and resveratrol (RGM) or placebo. At baseline, medical history, physical exam, cognitive tests are obtained. An ECG and a panel consisting CBC, electrolytes, liver and renal function tests will be drawn at the screening visit. Clinical information is obtained from the identified caregiver. The study drug (RGM or placebo, depending on which group the subject is randomly assigned to) is dispensed at baseline. Follow up visits at months 3, 6, 9, and 12 months require physical exam and some cognitive measures. At Month 12 a neurological exam will be performed. Adverse events are collected at each visit. Medication compliance is assessed at months 3, 6, 9, and 12 months and unused study drug is retrieved. At Month 12 unused study drug is retrieved and no more study drug is dispensed. Clinical information is obtained from the caregiver at each visit. At the Month 12 visit, a questionnaire will be completed by the study staff, subject and study partner to assess the adequacy of medication blinding. As noted all of the above tests and procedures are part of the research protocol. At study termination the subject will be referred to ongoing clinical care as appropriate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Alzheimer's Disease

Keywords

Alzheimer's Disease, Dementia, Nutritional Supplement, Resveratrol

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

27 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Arm 1

Arm Type

Placebo Comparator

Arm Description

Liquid placebo

Arm Title

Arm 2

Arm Type

Experimental

Arm Description

Liquid Resveratrol with Glucose, and Malate

Intervention Type

Dietary Supplement

Intervention Name(s)

Resveratrol with Glucose, and Malate

Intervention Description

Dietary supplement delivered in grape juice

Intervention Type

Dietary Supplement

Intervention Name(s)

Placebo

Intervention Description

Liquid placebo

Primary Outcome Measure Information:

Title

Alzheimer Disease Assessment Scale (ADAScog)

Time Frame

one year

Secondary Outcome Measure Information:

Title

CGIC

Time Frame

one year

10. Eligibility

Sex

All

Minimum Age & Unit of Time

50 Years

Maximum Age & Unit of Time

90 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Consenting individuals as defined by IRB guidelines NINCDS/ADRDA criteria for probable AD Community dwelling Age: greater than or equal to 50 years MMSE between 12 and 26, inclusive Stable medical condition for 3 months prior to screening visit Stable doses of (non excluded) medications with central nervous system activity for 4 weeks prior to the screening visit (For cholinesterase inhibitors there should be no plan of dose escalation) Physically acceptable for this study as confirmed by medical history, physical exam, neurologic exam and clinical laboratory tests Supervision available for administration of study medications Study partner to accompany subject to all scheduled visits and complete informant-based assessments. Fluent in English or Spanish Modified Hachinski < 4 CT or MRI since onset of memory impairment demonstrating absence of clinically significant focal lesion (One lacune in a non-critical brain region is acceptable) Able to complete baseline assessments 6 years of education, or work history sufficient to exclude mental retardation Able to ingest oral medication Exclusion Criteria: Active liver disease or persistent elevation in serum transaminase Severe renal disease - Hx of diabetes mellitus (both insulin-dependent and non-insulin-dependent) or blood glucose >150 mg/dl Active neoplastic disease (skin tumors other than melanoma are not exclusionary; subjects with stable prostate cancer or other stable cancers may be included at the discretion of the PI (Sano)) Use of another investigational agent within 2 months of the screening visit History of clinically significant stroke Current evidence or history in the past 2 years of seizures, head injury with loss of consciousness and/or immediate confusion after the injury Current DSM-IV criteria-based diagnosis for major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse. Blindness, deafness, language difficulties or any other disability which may interfere with testing ability In female subjects, no history of menopause Use of medications containing aluminum hydroxide, including anti-ulcer antacids such as Alternagel, Amphojel, Alu-tab, Maalox and Mylanta

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Mary Sano, PhD

Organizational Affiliation

James J. Peters Veterans Affairs Medical Center

Official's Role

Principal Investigator

Facility Information:

Facility Name

James J. Peters VA Medical Center, Bronx, NY

City

Bronx

State/Province

New York

ZIP/Postal Code

10468

Country

United States

12. IPD Sharing Statement

Citations:

PubMed Identifier

30480082

Citation

Zhu CW, Grossman H, Neugroschl J, Parker S, Burden A, Luo X, Sano M. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y). 2018 Nov 9;4:609-616. doi: 10.1016/j.trci.2018.09.009. eCollection 2018.

Results Reference

derived

Learn more about this trial

Randomized Trial of a Nutritional Supplement in Alzheimer's Disease

We'll reach out to this number within 24 hrs